Improvement Effect and Regulation Mechanism of Oyster Peptide on Dexamethasone-Induced Osteoporotic Rats.

IF 5.4 2区医学 Q1 CHEMISTRY, MEDICINAL

Marine Drugs Pub Date : 2025-09-11 DOI:10.3390/md23090356

Wei Yang, Wenyu Ma, Xiaoming Qin, Wenhong Cao, Haisheng Lin

{"title":"Improvement Effect and Regulation Mechanism of Oyster Peptide on Dexamethasone-Induced Osteoporotic Rats.","authors":"Wei Yang, Wenyu Ma, Xiaoming Qin, Wenhong Cao, Haisheng Lin","doi":"10.3390/md23090356","DOIUrl":null,"url":null,"abstract":"<p><p>The increasing global population of the elderly and rising life expectancy have made osteoporosis a more severe public health issue, necessitating the development of safer and more effective therapeutic strategies. This study investigated the osteoprotective effects of low, medium, and high doses of oyster peptide (OP) in dexamethasone (DEX)-induced osteoporotic rats. Pathological analysis showed that OP treatment effectively mitigated bone loss and repaired bone microarchitecture deterioration caused by DEX administration. In the OP groups, levels of the osteogenic markers osteocalcin (OCN) and osteoprotegerin (OPG) were significantly higher than in the DEX group. Moreover, levels of the osteoclastic markers RANKL, Cathepsin K (Cath-K), MMP-9, C-terminal telopeptide of type I collagen (CTX-1), and Deoxypyridine (DPD) were significantly lower. Bone proteomic analysis of the DEX and OP groups revealed that differentially expressed proteins were significantly enriched in pathways related to extracellular matrix and structural reorganization, ECM-receptor interaction, and PI3K-Akt signaling. Furthermore, virtual screening simulations indicated that peptides with lengths ranging from 11 to 20 amino acid residues were involved in modulating the activity of key receptors in these pathways, including Integrins α5β1, Integrins αvβ3, and EGFR. Collectively, these results demonstrate the significant potential of OP as a novel therapeutic agent for osteoporosis.</p>","PeriodicalId":18222,"journal":{"name":"Marine Drugs","volume":"23 9","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12472170/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Marine Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/md23090356","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

The increasing global population of the elderly and rising life expectancy have made osteoporosis a more severe public health issue, necessitating the development of safer and more effective therapeutic strategies. This study investigated the osteoprotective effects of low, medium, and high doses of oyster peptide (OP) in dexamethasone (DEX)-induced osteoporotic rats. Pathological analysis showed that OP treatment effectively mitigated bone loss and repaired bone microarchitecture deterioration caused by DEX administration. In the OP groups, levels of the osteogenic markers osteocalcin (OCN) and osteoprotegerin (OPG) were significantly higher than in the DEX group. Moreover, levels of the osteoclastic markers RANKL, Cathepsin K (Cath-K), MMP-9, C-terminal telopeptide of type I collagen (CTX-1), and Deoxypyridine (DPD) were significantly lower. Bone proteomic analysis of the DEX and OP groups revealed that differentially expressed proteins were significantly enriched in pathways related to extracellular matrix and structural reorganization, ECM-receptor interaction, and PI3K-Akt signaling. Furthermore, virtual screening simulations indicated that peptides with lengths ranging from 11 to 20 amino acid residues were involved in modulating the activity of key receptors in these pathways, including Integrins α5β1, Integrins αvβ3, and EGFR. Collectively, these results demonstrate the significant potential of OP as a novel therapeutic agent for osteoporosis.

查看原文本刊更多论文

牡蛎肽对地塞米松诱导的骨质疏松大鼠的改善作用及调节机制。

全球老年人口的增加和预期寿命的延长使骨质疏松症成为一个更严重的公共卫生问题，因此有必要制定更安全、更有效的治疗战略。本研究探讨了低、中、高剂量牡蛎肽（OP）对地塞米松（DEX）所致骨质疏松大鼠的骨保护作用。病理分析表明，OP治疗可有效减轻骨丢失，修复DEX引起的骨微结构恶化。OP组成骨标志物骨钙素（OCN）和骨保护素（OPG）水平明显高于DEX组。此外，破骨细胞标志物RANKL、Cathepsin K （cat -K）、MMP-9、I型胶原c端末端肽（CTX-1）和脱氧吡啶（DPD）水平显著降低。DEX和OP组的骨蛋白质组学分析显示，与细胞外基质和结构重组、ecm受体相互作用和PI3K-Akt信号通路相关的差异表达蛋白显著富集。此外，虚拟筛选模拟表明，长度在11到20个氨基酸残基之间的肽参与调节这些通路中关键受体的活性，包括整合素α5β1、整合素αvβ3和EGFR。总的来说，这些结果表明OP作为一种新的骨质疏松治疗剂的巨大潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Marine Drugs 医学-医药化学

CiteScore

9.60

自引率

14.80%

发文量

671

审稿时长

1 months

期刊介绍： Marine Drugs (ISSN 1660-3397) publishes reviews, regular research papers and short notes on the research, development and production of drugs from the sea. Our aim is to encourage scientists to publish their experimental and theoretical research in as much detail as possible, particularly synthetic procedures and characterization information for bioactive compounds. There is no restriction on the length of the experimental section.